This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A compound of formula I



I,

in which

R^1 is H or A,

$R^{2'}$, $R^{2''}$, $R^{2'''}$ are each, independently of one another, H, A, OH, OCH_3, OCF_3, Hal, CN, $COOR^1$, $CONR^1$ or NO_2,

R^3 is A, Ar or A-Ar,

R^4 is H or A,

A is unbranched or branched alkyl having 1-10 carbon atoms, in which one or two CH_2 groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or 1-7 H atoms may be replaced by F,

Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^4, $N(R^4)_2$, NO_2, CN, $COOR^4$, $CON(R^4)_2$, NR^4COA, $NR^4CON(R^4)_2$, NR^4SO_2A, COR^4, $SO_2N(R^4)_2$ or SO_2A,

A-Ar is arylalkyl, where A and Ar have one of the above-mentioned meanings,

Hal is F, Cl, Br or I, and

n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10,

or a pharmaceutically acceptable salt thereof.

2. (Previously Presented) A compound according to Claim 1, in which R^1 is hydrogen.

3. (Previously Presented) A compound according to Claim 1, in which $R^{2'}$, $R^{2''}$, $R^{2'''}$ are hydrogen.

4. (Currently Amended) A compound according to claim 1, in which R^3 is n-propyl, i-propyl, n-butyl, 2,2,2-trifluoroethyl, phenyl, benzyl or 2-nitrophenylmethyl.

5. (Currently Amended) A compound according to claim 1, in which n is 1.

6. (Currently Amended) A compound according to Claim 1, which is
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-C-phenylmethanesulfonamide,
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-C-[2-nitrophenyl]methanesulfonamide,
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]benzenesulfonamide,
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]- 2-propanesulfonamide,
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-1-butanesulfonamide,
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-1-propanesulfonamide, or
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-1-2,2,2-trifluoroethanesulfonamide,
or a pharmaceutically acceptable salt thereof.

7. (Currently Amended) A process for preparing a compound of formula I according to claim1 or a pharmaceutically acceptable salt thereof, comprising
a) reacting a compound of formula V



V,

in which R is a nucleophilic leaving group suitable for nucleophilic substitution on an aromatic compound with a compound of formula VI



VI,

in which $R^{2'}$, $R^{2''}$, $R^{2'''}$ and n are as defined for the compound of formula I, giving a compound of formula IV



IV,

b) converting the compound of formula IV by hydrogenation and optionally alkylation into a compound of formula II



II,

in which R^1 is as defined for the compound of formula I, which is then

c) reacted with a compound of the formula III



~~Error! Bookmark not defined.~~ III,

in which R3 is as defined for the compound of formula I, and L is a nucleophilic leaving group, giving a compound of formula I,

and optionally a protecting group is subsequently cleaved off,

and/or a base or acid of a compound of formula I is converted into one of its salts.

8. (Cancelled)

9. (Cancelled)

10. (Cancelled)

11. (Withdrawn and Currently Amended) A pharmaceutical composition comprising a compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, [[,]] and a pharmaceutically acceptable excipient and/or adjuvant.

12. (Previously Presented) A pharmaceutical composition according to claim 11, further comprising at least one further pharmaceutically active ingredient.

13. (Withdrawn) A method for the prophylaxis or treatment of a disease in which the binding of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof to a nicotinic and/or muscarinic acetylcholine receptor leads to an improvement in the clinical picture comprising administering to a patient in need thereof an effective amount of the compound of formula I or a pharmaceutically acceptable salt thereof.

14. (Withdrawn) A method for the prophylaxis or treatment of schizophrenia, depression, an anxiety state, dementia, Alzheimer's disease, Lewy bodies dementia, a neurodegenerative disease, Parkinson's disease, Huntington's disease, Tourette's syndrome, a learning or memory impairment, age-related memory impairment, amelioration of withdrawal symptoms in nicotine dependence, stroke or brain damage by a toxic compound, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 11.

15. (Cancelled)

16. (Previously Presented) A process for preparing a pharmaceutical composition according to claim 11, comprising converting said composition into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

17. (Withdrawn) A set or kit comprising separate packs of
(a) an effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof, and
(b) an effective amount of a further pharmaceutically active ingredient.

18. (Withdrawn) A method for the prophylaxis or treatment of schizophrenia, depression, an anxiety state, dementia, Alzheimer's disease, Lewy bodies dementia, a neurodegenerative disease, Parkinson's disease, Huntington's disease, Tourette's syndrome, a learning or memory impairment, age-related memory impairment, amelioration of withdrawal symptoms in nicotine dependence, stroke or brain damage by a toxic

compound, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 12.

19-20. (Cancelled)

21. (Previously Presented) An isolated stereoisomer of a compound of formula I according to claim 1.

22. (Previously Presented) A mixture of stereoisomers of a compound of formula I according to claim 1.

23. (Currently Amended) A compound of formula I



I,

in which

R^1	is H or A,
$R^{2'}$, $R^{2''}$, $R^{2'''}$	are each, independently of one another, H, A, OH, OCH_3, OCF_3, Hal, CN, $COOR^1$, $CONR^1$ or NO_2,
R^3	is A, Ar or A-Ar,
R^4	is H or A,
A	is unbranched or branched alkyl having 1-10 carbon atoms, in which one or two CH_2 groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or 1-7 H atoms may be replaced by F,
Ar	is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR^4, $N(R^4)_2$, NO_2, CN, $COOR^4$, $CON(R^4)_2$, NR^4COA, $NR^4CON(R^4)_2$, NR^4SO_2A, COR^4, $SO_2N(R^4)_2$ or SO_2A,
A-Ar	is arylalkyl, where A and Ar have one of the above-mentioned meanings,
Hal	is F, Cl, Br or I, and

n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10~~;~~

~~or a pharmaceutically acceptable salt or solvate thereof~~.

24. (Cancelled)